ZHAOKE OPHTH-B(06622) Manufacturing Site Receives GMP Certification from Australia's Therapeutic Goods Administration

ZHAOKE OPHTH-B(06622) announced that the Company's manufacturing site in Nansha, Guangzhou, China, has recently obtained Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA). Australia is a full member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and its GMP inspection results are highly mutually recognized among PIC/S member authorities. The TGA GMP certification marks further recognition of the Company's production and quality management systems at its manufacturing facilities by an international drug regulatory authority. As multiple products continue to advance overseas registration and commercialization, the Company's production and quality management systems, which comply with international regulatory requirements, will provide important support for the relevant products to enter more overseas markets in the future and for the Company's continued advancement of its globalization strategy.